Faricimab: First Approval

Article Medicine, General & Internal

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jeffrey S. Heier et al.

Summary: The primary results of two Phase 3 trials show that faricimab can effectively improve visual acuity for patients with nAMD at intervals of up to 16 weeks, with comparable safety profile to aflibercept. This suggests that faricimab has the potential to reduce treatment burden by extending the time between injections while maintaining efficacy.

LANCET (2022)

添加到收藏夹

Article Medicine, General & Internal

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Charles C. Wykoff et al.

Summary: This study demonstrates the efficacy and safety of faricimab in patients with diabetic macular edema. Treatment with faricimab every 8 weeks or personalized treatment interval dosing achieved non-inferiority and had good tolerability.

LANCET (2022)

添加到收藏夹

Article Ophthalmology

Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes

Thomas A. Ciulla et al.

Summary: The study evaluated visual acuity outcomes and anti-vascular endothelial growth factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO) patients. Patients with better baseline visual acuity may experience loss of vision at 1 year, while those with moderately severe baseline impairment could improve with more injections. Visual outcomes are correlated with treatment intensity at 1 year.

BRITISH JOURNAL OF OPHTHALMOLOGY (2021)

添加到收藏夹

Review Ophthalmology

Angiopoietins as Potential Targets in Management of Retinal Disease

Arshad M. Khanani et al.

Summary: The Ang/Tie2 pathway complements VEGF-mediated activity in retinal vascular diseases by decreasing vascular integrity, increasing neovascularization, and increasing inflammatory signaling. Faricimab, a bispecific antibody targeting VEGF and Ang2, has shown positive results in patients with DME and AMD, potentially changing the treatment landscape.

CLINICAL OPHTHALMOLOGY (2021)

添加到收藏夹

Review Ophthalmology

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES A Review

Jeffrey S. Heier et al.

Summary: This review aims to provide ophthalmologists and practicing retina specialists with an overview of clinical evidence and therapeutic potential of targeting the angiopoietin/Tie pathway in retinal vascular diseases. Literature search and clinical trials suggest that drugs targeting this pathway may have potential benefits in treating retinal vascular diseases due to the synergistic nature of the pathways involved.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)

添加到收藏夹

Article Ophthalmology